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Background: Bacterial vaginosis is associated with increased transmission of sexually transmitted infections,
preterm labor, post-surgical infections, and endometritis. Current treatment for symptomatic bacterial vaginosis
includes antibiotics, such as metronidazole, which are 70–80 % effective at one month after treatment and result in
high recurrence rates and secondary candida infections. Intravaginal boric acid has been used for over a hundred
years to treat vaginal infections, such as bacterial vaginosis. Boric acid is inexpensive, accessible, and has shown to
be an effective treatment for other infections, such as vaginal candidiasis. To date, there has been no clinical trial
evaluation of boric acid effectiveness to treat bacterial vaginosis.
Methods/Design: The BASIC (Boric Acid, Alternate Solution for Intravaginal Colonization) trial is a randomized,
double-blinded, multicenter study. The study will enroll a minimum of 240 women of 16–50 years of age who are
symptomatic with bacterial vaginosis. Eligible participants will have Amsel and Nugent scores confirming bacterial
vaginosis. Women who are pregnant or menopausal or have other active co-infections will be excluded.
Consenting participants who meet exclusion and inclusion criteria will be randomly assigned to one of three
treatment groups: boric acid, metronidazole, or an inert placebo. Self-administration of treatment intravaginally for
10 days will be followed by clinical assessment at 7 and 30 days (days 17 and 40, respectively) after the end of the
treatment phase. Primary outcome is a non-inferiority, per-protocol comparison of the effectiveness of boric acid
with that of metronidazole at day 17, as measured by the Nugent score in 16–50 year olds. Secondary outcomes
include: non-inferiority, intention-to-treat comparison of effectiveness of boric acid with that of metronidazole at
day 17, analysis for both per-protocol and intention-to-treat at day 40, and safety considerations, including adverse
effects requiring patient discontinuation of treatment.
Discussion: This study will be the first to determine whether intravaginal boric acid is non-inferior to metronidazole
in the treatment of bacterial vaginosis in symptomatic women.
Trial registration: ClinicalTrials.gov NCT00799214, registered online Nov 10, 2008.
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Bacterial vaginosis (BV) is thought to be more common
than either vulvovaginal candidiasis or trichomoniasis,
and to represent 40–50 % of all cases of vaginitis [1].
Bacterial vaginosis is associated with postpartum endo-
metritis, increased risk of post-surgical infections, pelvic
inflammatory disease, increased risk of spontaneous
abortions, preterm rupture of membranes and delivery,
and increased risk of sexually transmitted infection ac-
quisition, including: human immunodeficiency virus,
herpes simplex virus, Neisseria gonorrhoeae, Chlamydia
trachomatis, and Trichomonas vaginalis [1–6]. Bacterial
vaginosis is caused by a shift from the normal peroxidase-
producing lactobacillus-dominant vaginal flora to a
several-log increase in total bacterial colony count, which
may include a mix of anaerobes, genital mycoplasmas,
and Gardnerella vaginalis [1, 7]. Bacterial vaginosis is
classically characterized by abnormal odor and vaginal dis-
charge in symptomatic women, while 50 % of women with
BV are asymptomatic [7, 8]. It can also be painful, and is
associated with dysuria or dyspareunia in symptomatic
women [8]. Bacterial vaginosis is diagnosed in the pres-
ence of three of the four Amsel criteria: elevated pH
(>4.5); homogenous milky or creamy discharge; amine
odor; and clue cells [4, 7, 9]. The gold standard for BV
diagnosis is by Gram staining (Nugent score ≥7), demon-
strating a decrease or absence of lactobacilli and the pres-
ence of other microbes that cause BV [4, 7, 9, 10].
Untreated women show a 30 % spontaneous resolution
rate for BV [11, 12]. Current recommended antimicro-
bial treatments for BV in non-pregnant, symptomatic
women include oral and intravaginal metronidazole or
clindamycin [1, 8, 13]. Oral and intravaginal metronida-
zole are considered equivalent and effective treatments
for BV [9, 11, 14–16].
Standard treatment with metronidazole, according
to these trials, has imperfect cure rates (approxi-
mately 70–80 %) measured 1 month after treatment
[9, 11, 12, 15–18] and high BV recurrence risks: 33 %
at 3 months [19] and approximately 49–66 % at 1
year [18]. Metronidazole also carries a significant rate of
side effects (10–20 % of women), especially with the oral
metronidazole preparation [20], including secondary vagi-
nal infection with candida [12, 14, 16]. At present, oral or
vaginal metronidazole is the only recommended treatment
option for recurrent BV, as is vaginal metronidazole for
long-term suppression [9, 21].
Boric acid (H3BO3) has been used for over a hun-
dred years for the treatment of vaginal infections and
is commonly used by physicians and patients as an
inexpensive, easy to use, accessible treatment of can-
didiasis and BV [22]. In addition to its proven effective-
ness in the treatment of candidal infections, [22–31]
including those that did not resolve with usual antifungaltreatment [24–28], H3BO3 use seemed to be associated
with a reduced number of co-infections with BV [25]. A
retrospective study suggests clinical improvement in seven
of nine patients following treatment with 600 mg intrava-
ginal H3BO3 for 14 nights in women with a mixed infec-
tion of T. glabrata vaginitis and BV [25]. In an
uncontrolled, non-randomized, retrospective chart review,
when H3BO3 was added to nitroimidazole there was
promising long-term (>88 % cure rate at 12 weeks after
the study and 50 % at 36 weeks of follow-up) suppression
of recurrent BV [32]. Based on the aforementioned study,
the physician evidence reference resource ‘UpToDate®’
[21] recommends that intravaginal H3BO3 (600 mg for 21
days) be added to 7 days of metronidazole or tinidazole
treatment to induce a remission prior to long-term sup-
pression therapy. No studies to date have determined
H3BO3 effectiveness in the treatment of acute, chronic, or
recurrent BV.
The objective of this study was to determine whether
intravaginal H3BO3 is comparable to standard treatment,
metronidazole, for the cure of BV in symptomatic women.
Research question
Among women 16–50 years old symptomatic with BV, is
intravaginal treatment with H3BO3 non-inferior to
metronidazole to achieve a Nugent score <7 (cure) by
day 17?
Null hypothesis
H0: proportion of women cured using H3BO3 ≤ metro-
nidazole proportion of women cured using metronida-
zole − 10 %.
Methods/Design
Study design
Institutional review board approval was granted for this
study through the University of British Columbia Clinical
Research Ethics Board (H07-02330). Health Canada
Clinical Trial Application Notice of Authorization was ob-
tained on 10 May 2013 (company code 31784, file number
187476). This trial is registered with ClinicalTrials.gov
(NCT00799214). This study conforms to CONSORT
2010 guidelines for randomized control trials.
Based on preliminary data, the success rate for the
boric acid treatment group is predicted to be approxi-
mately 77–88 % [25, 32] in treating BV. Metronidazole
would be expected to be 70–80 % [11, 12, 15–18] effect-
ive in treating BV, as compared with a 30 % success rate
of a placebo group [11, 12]. The Nugent score is found
to be >95 % sensitive [33] for detecting BV. We chose a
non-inferiority limit of 10 %, as this will allow for a clin-
ically relevant difference between the metronidazole
treatment group and the boric acid group. Also, this is
approximately 25 % of the expected difference between
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ment group and the placebo group. Accounting for a
non-inferiority limit (delta) of 10 %, testing for a signifi-
cance level of 0.05 and power of 80 %, we require ap-
proximately 63 subjects per group. To allow for a
dropout rate of 25 %, we set a target rate of 80 subjects
per treatment arm. If there is a true difference in favor
of the experimental treatment of 8 %, then 126 patients
(total for two groups of 63) are needed, to be 80 % sure
of the upper limit of a one-sided 95 % confidence inter-
val, using a binary outcome, non-inferiority trial power
calculator [34].
We felt it important to include a placebo treatment
arm in this study for different reasons: (1) this is the first
randomized controlled trial to use intravaginal H3BO3;
thus, comparing it to placebo for safety and effectiveness
would be of clinical interest (that is, perhaps it is not
comparable to metronidazole in effectiveness but it is
still significantly better than placebo), (2) having a pla-
cebo group in a non-inferiority trial acts as a sensitivity
assay and internal validator for this type of trial [35], (3)
comparing metronidazole effectiveness and safety with
results obtained for a placebo group in 16–19-year-olds
has not previously been done and would also be of
clinical interest.
Study setting
Recruitment began February 2014 for a minimum of 240
volunteers through participating family practice clinics
in British Columbia, Canada. Volunteer participating
clinics represent a spectrum of different types of practice
across British Columbia: rural, remote, urban, First
Nations and non-First Nations communities, single
and multi-clinician practices, general family practice of-
fices, women’s health clinics, and youth clinics. Clinics
were recruited to the study through province-wide medical
journal advertisements, university family practice depart-
mental email advertisements, personal emails, faxes, phone
calls and in person. Eligible clinics agreed to recruit five or
more participants meeting inclusion and exclusion criteria
and to use the study treatments and prepared packages
provided.
Participants and eligibility
Women who present to their clinician at participating
family practice clinics with symptoms of BV are offered
an opportunity to participate in the study. Participants
are given the informed consent form explaining the
three possible treatment arms, and that participation
will include three visits (the initial visit, day 0; day 17–19
[7–9 days after the treatment end to measure the primary
endpoint]; and day 40–42 [30–32 days after the treatment
end as a secondary endpoint]) involving three examina-
tions, including a pregnancy test. There are no visits tothe clinic while the participants are administering the
10-day treatment unless there are any concerns. Women
are included in the study if they are symptomatic for BV,
meet three of four Amsel criteria on the initial day of the
study and subsequently have a swab graded with a Nugent
score ≥7. Detailed eligibility criteria are listed in Table 1.
In general, participants cannot be pregnant, menopausal,
have another vaginal infection, or have an intrauterine
device. Written consent is obtained prior to treatment
intervention. Women who choose to participate receive
their medication for free. There is a draw for recruited
women to win a small gift certificate.
Randomization
Randomization in blocks of 80 was conducted by the
study pharmacist (who was blinded to enrollment and
outcome measurement) using the ‘first generator’ on
the website: www.randomization.com in September
2013. These numbers then become the new identifica-
tion numbers on the treatment packs. All treatment
packs are then distributed to participating clinics by
the study pharmacist who sends out five sequentially
numbered treatment packs to each participating site
as sites are recruited to the study. The study pharma-
cist is the only person with access to the master code
to the randomized treatments. The participants,
recruiting clinicians and investigators will be blinded
to the controlled and randomized 10-day treatment
pack that is given to the study participant. Blinded
recruiting clinicians give out the physically indistinguish-
able treatment package in allocated randomization order
to the sequential participants on enrollment day (day 0).
Subsequently the treatment pack number becomes the
participants’ identification number.
Intervention and control groups
On day 0, the enrolled participants will be blindly
and randomly assigned to one of three 10-day treat-
ments (minimum of 80 women per treatment arm):
(1) placebo (emollient cream); (2) H3BO3 (600 mg
H3BO3 compounded in emollient cream); (3) metro-
nidazole (10 %, for a total of 37.5 mg metronidazole)
intravaginal cream (Sanofi-Aventis Canada Inc. Product
DIN 01926861) packaged by the study pharmacist. There
is no detectable difference between the treatments in
either appearance or scent.
Study procedure and data collection
On day 0, a pregnancy test will be conducted and history will
be collected by the clinician. During a pelvic examination,
the clinician will ensure intact mucous membranes and
anatomy, observe whether there is homogenous milky
or creamy discharge (one of the four Amsel criteria),
take swabs for chlamydia and gonorrhea, BV (for the
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
Must be 16–50 years old and pre-menopausal. Capable of giving written
informed consent.
Younger than 16 or post-menopausal.
Fluent spoken and written English. Menstruating at diagnosis.
Agrees to examination on enrollment day, day 17–19 and day 40–42. Symptoms so severe as to make allocation to placebo unacceptable to
the woman.
Has a negative pregnancy test during the study. Agrees to follow study
protocol and is reliable for follow-up.
Currently pregnant or at high risk for pregnancy.
Has documented bacterial vaginosis infection by positive vaginal swab
(minimum Nugent score of ≥7) and meets three of four Amsel criteria.
Current active sexually transmitted infection (chlamydia, gonorrhea,
trichomonas).
Agrees to refrain from vaginal intercourse for the 10 days of treatment
(or to use non-lubricated non-latex condoms if unavoidable). Agrees not
to douche or use any intravaginal products during treatment (including
tampons, medications, devices).
Current yeast infection as determined by history, physical examination,
and swab analysis.
Agrees to abstain from alcohol during the 10 days of treatment (from
24 hours before through 72 hours after taking study medication).
History of pelvic inflammatory disease. Allergy to metronidazole.
Agrees to no new medications or antibiotics during treatment. Currently breast feeding.
Has no currently active sexually transmitted infection as determined by
history, physical examination, and swab analysis negative for chlamydia,
gonorrhea, candidiasis, or trichomonas.
Any open wound, excoriation, or vaginal irritation, including Bartholin’s
cyst, abscess, and herpes simplex viral lesion, as determined by physical
exam.
Presence of another vulvar, vaginal or medical condition, including
cervical neoplasia or treatment, or medical device, including intrauterine
device, that might confound treatment response.
Using lithium, anticoagulants or disulfiram drugs.
Any antifungal or antibiotic use 14 days prior to enrolment.
Papanicolaou smear taken within one week of enrolment.
Meeting three of four Amsel criteria but having a Nugent score <7.
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form a Whiff test using a provided standardized 10 %
potassium hydroxide solution (one of the four Amsel
criteria). Vaginal discharge will also be tested for pH
(one of the four Amsel criteria). Where facilities permit;
clue cells will be examined, as the fourth Amsel criterion.
On this day, the recruiting clinician will confirm partici-
pation, eligibility, and exclusion criteria using provided
protocol forms and will collect the signed consent form
and the demographic and medical history questionnaires
provided.
The blinded treatment pack (containing either H3BO3
compounded in emollient cream, metronidazole cream,
or emollient cream) is allocated by the recruiting clin-
ician in the randomization order to sequential partici-
pants on day 0. The participant package also contains:
(1) vaginal applicator; (2) pads; (3) non-lubricated non-
latex condoms; (4) a diary to record daily use of the
treatment (5) information sheet outlining follow-up in-
structions and emergency contact numbers for the study
members. Participants will self-administer the blinded
treatment cream intravaginally each evening immedi-
ately prior to sleep for 10 days. The participants will be
instructed to use a provided pad during day and night.Each participant will record daily compliance, side effects,
and symptoms in the journal provided.
On both follow-up visits: days 17–19 (one week after
the treatment end) and 40–42 (one month after the treat-
ment end), the participant will return to the clinic that
enrolled her for reassessment, a pregnancy test, and a
follow-up examination, including a pelvic examination
and repeat swab analysis. It will be noted whether her
BV symptoms are still present, and if she had any side ef-
fects or problems during treatment. The participant will
also return her daily treatment diary on the day 17 visit.
Safety assessments
Emergency telephone contact with the investigators will
be available for any questions or problems related to the
treatment. On day 5 of the treatment, the participant
will receive a call, text, or email from one of the investi-
gators to determine and record compliance, side effects,
BV symptoms, and satisfaction with treatment. The
study pharmacist will be informed by the recruiting clin-
ician of the participant’s full name, date of birth, and
personal health number, and the study number assigned,
so that the study pharmacist can enter the medication
name into the British Columbia PharmaNet Database
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ensures that subsequent treating physicians throughout
the province will have access to details of the treatment
received, in case of a safety concern and a need to un-
blind the participant’s medication should the participant
present with an emergency. Non-emergency access to
the provincial pharmacy database is not allowed, to protect
the participant’s identification of the blinded treatment.
If at any time the participant reports intolerable side
effects (vaginal discomfort, intolerable vaginal discharge,
urticaria, or secondary yeast infection) during treatment,
or exacerbation of symptoms at any point, she may vol-
untarily discontinue the treatment and leave the study
without prejudice, and her doctor or another physician
may provide treatment as per usual standard of care.
As neither metronidazole nor H3BO3 treatments pro-
vided to patients are in amounts considered toxic when
taken intravaginally or if accidentally ingested, should
there be any occurrence of serious adverse effects
(neurological, cardiac, respiratory, gastrointestinal, or
anaphylactic reactions) during any of the treatments, the
study will be put on hold until an investigation can be
held. In the case of serious adverse effects found to be
caused by the treatment, the study will be stopped, and
the study unblinded and decoded by the study pharma-
cist. The investigators, participants, and clinicians in-
volved in the study would be informed for the reason for
stopping the study.
Outcomes and assessment
On days 17–19 and days 40–42, if the vaginal swab is
positive for BV found by both meeting three of four
Amsel criteria and having a Nugent score ≥7 and the
participant is symptomatic for BV, the physician will pre-
scribes a standard medication of his choice. This is con-
sidered a treatment failure addressing our primary and
secondary outcomes: effectiveness at 7 days and 30 days
after treatment end.
If the participant discontinued the treatment during
the 10 days because of side effects or complained of in-
tolerable side effects (major adverse effects) from the
treatment, this is considered a treatment failure referring
to our secondary outcome: safety.
Statistical considerations
The primary outcome measure is a non-inferiority per-
protocol comparison of effectiveness of H3BO3 with
metronidazole at day 17, as measured by Nugent score, in
16–50-year-olds with a z-based confidence interval for the
difference of two proportions. This was chosen as the pri-
mary outcome measure because the immediate effect of
H3BO3 after a 10-day treatment compared with metro-
nidazole was our most important question about BV treat-
ment. A change from a baseline Nugent score ≥7 to aNugent score <7 is considered a cure of BV. Treatment
failure will be reported as a positive Nugent score ≥7 at
day 17.
Secondary outcome measures include a non-inferiority
intention-to-treat comparison of effectiveness of H3BO3
with metronidazole at day 17, as measured by Nugent
score in 16–50-year-olds, with a z-based confidence
interval for the difference of two proportions. We will
use this comparison to confirm the robustness of our
per-protocol comparison but the per-protocol analysis
will be the primary determinant of the non-inferiority
test. In addition, we will conduct a non-inferiority com-
parison of effectiveness of H3BO3 and metronidazole at
day 40, as measured by Nugent score in 16–50-year-olds
analyzed on both per-protocol and intention-to treat
principles, with a z-based confidence interval for the dif-
ference of two proportions, and safety consideration in-
cluding intolerable adverse effects requiring patient
discontinuation of the 10-day treatment. To control for
multiple testing, we will use a Bonferroni-type correc-
tion. To account for both intention-to-treat and per-
protocol analyses, and two timepoint analyses, the
threshold for statistical significance will be set at 0.01
(approximately 0.05 divided by 4).
The following are tertiary outcome measures and no
formal sample size calculations were made. Minor ad-
verse effects (side effects not causing the patient to dis-
continue treatment) will be reported and compared
between the treatment arms but will not be considered
as treatment failure. We will examine the adolescent
population, the 16–19 year old subgroup, for non-
inferiority for effectiveness of H3BO3, as compared with
metronidazole, at the end of the study. Finally, we will
test for superiority of the effectiveness and safety of
H3BO3 compared with placebo in both the 16–50-year-
olds and in the 16–19 year old subgroup. In addition,
our study is the first to be able to examine 16–19-year-
olds for the effectiveness and safety of metronidazole
compared with placebo.
95 % confidence intervals will be established. Miss-
ing data (participants who fail to complete follow-up
for any reason) are accounted for by an anticipated
25 % lost-to-follow-up rate. Data will be blindly col-
lected by the outcome assessors from the participat-
ing clinics and entered into an electronic database.
The study pharmacist will provide the randomization
code for the data to a third-party statistician and the
data will be analyzed. Self-reported participant satis-
faction criteria included at the end of the daily treat-
ment diary will use a five-point rating scale to record:
effectiveness in curing BV symptoms, side effects, ease
of use, likelihood they would use it again for BV
treatment, likelihood they would recommend it to
someone else for BV treatment.
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The BASIC (Boric Acid, Alternate Solution for Intravagi-
nal Colonization) study will be the first prospective ran-
domized control trial to determine the effectiveness of
intravaginal H3BO3 compared with metronidazole for
the treatment of BV in symptomatic women. If intravagi-
nal H3BO3 is shown to be non-inferior to metronidazole
in the treatment of BV, this may provide women with
less costly options for treating this common vaginal
infection.
Trial status
The trial is currently open to recruitment.
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